PREVENTIVE FOR NORMAL LIPEMIC DIABETES MELLITUS II

PREVENTIVE FOR NORMAL LIPEMIC DIABETES MELLITUS II

PURPOSE: To obtain the subject preventive agent which contains bezafibrate as an active ingredient, gives the improvement of glucose content at stomach emptiness or after loading on the dietary test, and also lowers the triglyceride value and cholesterol value but they remain in the normal ranges. C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: BUARUTAA BETSUKU
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BUARUTAA BETSUKU
description PURPOSE: To obtain the subject preventive agent which contains bezafibrate as an active ingredient, gives the improvement of glucose content at stomach emptiness or after loading on the dietary test, and also lowers the triglyceride value and cholesterol value but they remain in the normal ranges. CONSTITUTION: Bezafibrate i.e., 2- 4-[2-(4-chlorobenzamide)-ethyl]phenoxy}-2- methylpropionic acid, which has been widely used for treatment of hyperlipemia is used as an active ingredient, and, when necessary, an additive insulin-emitting agent is admixed thereto. The dose is 200-600mg/day and the daily dose is preferably intaken between meals in the form of tablets or sugar-coated tablets. In the case that defective insulin secretion causes the diabetes, sulfonylurea, particularly an insulin emitter such as glibenclamide must be simultaneously given and both substance can be packed in a single dose unit.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JPS6471813A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JPS6471813A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JPS6471813A3</originalsourceid><addsrcrecordid>eNrjZDAKCHINc_UL8QxzVXDzD1Lw8w_ydfRR8PEMcPX1dFZw8XR0cg1xDVbwdfXx8QwJDVbw9ORhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfFeAcFmJuaGFobGjsZEKAEAPn8myA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PREVENTIVE FOR NORMAL LIPEMIC DIABETES MELLITUS II</title><source>esp@cenet</source><creator>BUARUTAA BETSUKU</creator><creatorcontrib>BUARUTAA BETSUKU</creatorcontrib><description>PURPOSE: To obtain the subject preventive agent which contains bezafibrate as an active ingredient, gives the improvement of glucose content at stomach emptiness or after loading on the dietary test, and also lowers the triglyceride value and cholesterol value but they remain in the normal ranges. CONSTITUTION: Bezafibrate i.e., 2- 4-[2-(4-chlorobenzamide)-ethyl]phenoxy}-2- methylpropionic acid, which has been widely used for treatment of hyperlipemia is used as an active ingredient, and, when necessary, an additive insulin-emitting agent is admixed thereto. The dose is 200-600mg/day and the daily dose is preferably intaken between meals in the form of tablets or sugar-coated tablets. In the case that defective insulin secretion causes the diabetes, sulfonylurea, particularly an insulin emitter such as glibenclamide must be simultaneously given and both substance can be packed in a single dose unit.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1989</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19890316&amp;DB=EPODOC&amp;CC=JP&amp;NR=S6471813A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19890316&amp;DB=EPODOC&amp;CC=JP&amp;NR=S6471813A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BUARUTAA BETSUKU</creatorcontrib><title>PREVENTIVE FOR NORMAL LIPEMIC DIABETES MELLITUS II</title><description>PURPOSE: To obtain the subject preventive agent which contains bezafibrate as an active ingredient, gives the improvement of glucose content at stomach emptiness or after loading on the dietary test, and also lowers the triglyceride value and cholesterol value but they remain in the normal ranges. CONSTITUTION: Bezafibrate i.e., 2- 4-[2-(4-chlorobenzamide)-ethyl]phenoxy}-2- methylpropionic acid, which has been widely used for treatment of hyperlipemia is used as an active ingredient, and, when necessary, an additive insulin-emitting agent is admixed thereto. The dose is 200-600mg/day and the daily dose is preferably intaken between meals in the form of tablets or sugar-coated tablets. In the case that defective insulin secretion causes the diabetes, sulfonylurea, particularly an insulin emitter such as glibenclamide must be simultaneously given and both substance can be packed in a single dose unit.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1989</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDAKCHINc_UL8QxzVXDzD1Lw8w_ydfRR8PEMcPX1dFZw8XR0cg1xDVbwdfXx8QwJDVbw9ORhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfFeAcFmJuaGFobGjsZEKAEAPn8myA</recordid><startdate>19890316</startdate><enddate>19890316</enddate><creator>BUARUTAA BETSUKU</creator><scope>EVB</scope></search><sort><creationdate>19890316</creationdate><title>PREVENTIVE FOR NORMAL LIPEMIC DIABETES MELLITUS II</title><author>BUARUTAA BETSUKU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JPS6471813A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1989</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BUARUTAA BETSUKU</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BUARUTAA BETSUKU</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PREVENTIVE FOR NORMAL LIPEMIC DIABETES MELLITUS II</title><date>1989-03-16</date><risdate>1989</risdate><abstract>PURPOSE: To obtain the subject preventive agent which contains bezafibrate as an active ingredient, gives the improvement of glucose content at stomach emptiness or after loading on the dietary test, and also lowers the triglyceride value and cholesterol value but they remain in the normal ranges. CONSTITUTION: Bezafibrate i.e., 2- 4-[2-(4-chlorobenzamide)-ethyl]phenoxy}-2- methylpropionic acid, which has been widely used for treatment of hyperlipemia is used as an active ingredient, and, when necessary, an additive insulin-emitting agent is admixed thereto. The dose is 200-600mg/day and the daily dose is preferably intaken between meals in the form of tablets or sugar-coated tablets. In the case that defective insulin secretion causes the diabetes, sulfonylurea, particularly an insulin emitter such as glibenclamide must be simultaneously given and both substance can be packed in a single dose unit.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_JPS6471813A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title PREVENTIVE FOR NORMAL LIPEMIC DIABETES MELLITUS II
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T13%3A35%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BUARUTAA%20BETSUKU&rft.date=1989-03-16&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJPS6471813A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true